

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2696)

SUPPLEMENTAL NOTICE OF EXTRAORDINARY GENERAL MEETING

Reference is made to the notice of the extraordinary general meeting (the “EGM”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) dated 1 December 2022 (the “**Original EGM Notice**”), which sets out the time and venue of the EGM and contains the resolution to be tabled before the EGM for shareholders’ approval, the circular dated 1 December 2022 (the “**Original Circular**”), the announcement on postponement of the EGM dated 9 December 2022, as well as the circular of the Company dated 13 December 2022 (the “**Supplemental Circular**”), which contains the details of the following resolution. Except as the context otherwise requires, capitalised terms used herein shall have the same meanings as ascribed to them in the Original EGM Notice, the Original Circular and the Supplemental Circular.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the EGM will be held as originally scheduled at Conference Room, 5th Floor, Innov Tower (Capitaland Building), Section A, 1801 Hongmei Road, Shanghai, PRC on Tuesday, 27 December 2022 at 11:00 a.m. for the purposes of considering and, if thought fit, passing the following resolution, in addition to the resolution set out in the Original EGM Notice:

ORDINARY RESOLUTION

2. To consider and, if thought fit, approve the license agreement dated 17 November 2022 entered into between the Company and Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) (the “**License Agreement**”) as set out in the circular of the Company dated 13 December 2022 (including the transactions contemplated thereunder); and to authorise any Director to exercise all powers which they consider necessary and do such other acts and things and execute such other documents which in their opinion may be necessary or desirable to implement the transactions contemplated under the License Agreement.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 13 December 2022

As at the date of this notice, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.

Notes:

- (1) Please refer to the Original EGM Notice for details of the other resolution proposed at the EGM.
- (2) All resolutions at the EGM will be taken by poll pursuant to the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) (the “**Hong Kong Listing Rules**”). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Hong Kong Listing Rules.
- (3) Any shareholder of the Company entitled to attend and vote at the EGM is entitled to appoint a proxy (or more than one proxy if he/she holds more than one share) to attend and on a poll, vote on his/her behalf. A proxy needs not be a shareholder of the Company. As the form of proxy published by the Company on the website of the Hong Kong Stock Exchange on 1 December 2022 (the “**Original Form of Proxy**”) sent together with the Original EGM Notice does not contain the additional ordinary resolution set out in this supplemental notice, a supplemental form of proxy (the “**Supplemental Form of Proxy**”) has been uploaded on the website of the Hong Kong Stock Exchange on 13 December 2022 and will be despatched to the shareholders of the Company together with this supplemental notice. If more than one proxy is so appointed, the Supplemental Form of Proxy shall specify the number of shares in respect of which each such proxy is so appointed. In case of a poll every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.
- (4) In order to be valid, the Supplemental Form of Proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be delivered to the Company’s Board secretary office (for holders of Domestic Shares or Unlisted Foreign Shares), at 9th Floor, Innov Tower (Capitaland Building), Section A, 1801 Hongmei Road, Shanghai, PRC or the Company’s H share registrar in Hong Kong (for holders of H shares), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 24 hours before the time appointed for the EGM (i.e. not later than 11:00 a.m on Monday, 26 December 2022) or the adjourned meeting (as the case may be). Completion and return of the Original Form of Proxy and/or the Supplemental Form of Proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
- (5) In order to determine the list of Shareholders who will be entitled to attend and vote at the EGM, the registers of members of the Company will be closed from Thursday, 22 December 2022 to Tuesday, 27 December 2022 (both dates inclusive), during which period no transfer of shares of the Company will be effected. Shareholders whose names appear on the registers of members of the Company on Tuesday, 27 December 2022 shall be entitled to attend and vote at the EGM. In order to qualify for attending and voting at the EGM, all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration by 4:30 p.m. on Wednesday, 21 December 2022.
- (6) Shareholders who attend the EGM in person or by proxy shall bear their own travelling and accommodation expenses.
- (7) References to time and dates in this supplemental notice are to Beijing time and dates.